Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
Portfolio Pulse from
Portage Biotech has resumed enrollment in the final cohort of the dose escalation phase for its Port-6 drug in the ADPORT-601 trial. The trial is progressing towards the first dual-administration of selective A2A and A2B antagonists in patients, supported by an encouraging safety profile.
March 12, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Portage Biotech has resumed enrollment in the final cohort of its ADPORT-601 trial for Port-6, supported by a positive safety profile. This marks progress towards dual-administration of A2A and A2B antagonists.
The resumption of enrollment in the final cohort of the ADPORT-601 trial indicates progress in Portage Biotech's clinical development. The encouraging safety profile is a positive sign, likely boosting investor confidence and potentially impacting the stock price positively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100